A research team led by Specially Appointed Professor Naoto Nemoto and Professor Koji Matsuoka at the Graduate School of Science and Engineering at Saitama University has identified a single-domain VHH antibody that specifically recognizes the three-dimensional structural characteristics of a single-stranded DNA aptamer. The findings, published in the journal Antibodies, demonstrate that antibody molecular recognition can extend beyond conventional protein targets to folded nucleic acid structures. Specifically, the researchers evaluated how this single-domain antibody interacts with a DNA aptamer that binds oxytetracycline, an antibiotic commonly used in veterinary medicine, revealing that the presence of the antibiotic alters the structural conformation of the aptamer and enhances antibody binding.
DNA aptamers are short, single-stranded DNA molecules that fold into defined shapes to selectively bind target molecules, including proteins and small chemical compounds. While aptamers have attracted significant attention as functional alternatives to antibodies in biosensors, diagnostic assays, and other biotechnology applications, most conventional research has focused exclusively on identifying nucleic acid sequences that capture specific ligands. The reverse paradigm—engineering proteins or antibodies capable of distinguishing the three-dimensional folded conformations of DNA aptamers—has remained largely unexplored. Identifying antibodies that recognize diverse folded tertiary structures of single-stranded DNA aptamers represents a distinct bioengineering challenge that could enable novel molecular sensing platforms capable of detecting conformational changes in nucleic acids.
To investigate whether small, single-domain antibodies could discriminate the tertiary structure of nucleic acids, the researchers conducted four rounds of in vitro selection using cDNA display technology. This directed screening process allowed the team to isolate candidate VHH antibodies against the oxytetracycline-binding DNA aptamer. Among the candidates obtained from the selection library, an antibody designated VHH6 emerged as a promising molecule capable of engaging the structural features of the DNA aptamer under defined experimental conditions.
Following candidate isolation, the researchers used surface plasmon resonance (SPR) spectroscopy to quantitatively characterize the binding kinetics and affinity of VHH6 toward the DNA aptamer in both the presence and absence of oxytetracycline. The SPR measurements confirmed that VHH6 preferentially binds the oxytetracycline-associated aptamer complex. Notably, VHH6 exhibited an approximately 4.2-fold increase in binding affinity for the DNA aptamer when oxytetracycline was present compared to when the antibiotic was absent, demonstrating that the presence of the small-molecule ligand directly modulates the stability and strength of the antibody–aptamer complex.
To determine whether the binding mechanism relied on the sequence-dependent tertiary shape rather than nonspecific interactions with nucleic acid constituents, the researchers tested VHH6 against a rearranged DNA control sequence. This scrambled sequence retained the identical overall base composition as the original aptamer but featured an altered nucleotide order. When exposed to this rearranged sequence, VHH6 exhibited substantially weaker binding, confirming that the antibody recognizes the specific sequence-dependent three-dimensional structure of the folded aptamer rather than general nucleotide motifs.
Computational structural modeling using AlphaFold3 provided additional molecular-level predictions regarding the interaction interface between VHH6 and the folded nucleic acid. According to the structural predictions, specific aromatic and positively charged amino acid residues located within the third complementarity-determining region (CDR3) of the VHH6 antibody are positioned to interact directly with the DNA bases and the negatively charged phosphate backbone of the aptamer. These computational insights suggest that electrostatic and stacking interactions mediated by the CDR3 loop contribute significantly to the antibody’s selective recognition of the aptamer’s tertiary conformation.
Doctoral candidate and first author Nayab Khaliq noted that the study explores molecular recognition from the opposite direction of standard aptamer research, shifting the focus from using nucleic acids to capture targets to employing antibodies to read out the conformational states of DNA itself. The experimental results establish that the folded geometry of a DNA aptamer and the binding of an associated ligand together govern antibody engagement, opening new routes for analyzing and engineering functional protein–nucleic acid interfaces.
The study authors highlighted that pairing target-binding DNA aptamers with conformation-sensitive VHH antibodies offers a foundational framework for dual-recognition detection systems. In such an analytical format, an aptamer could first capture a small chemical compound, after which an engineered antibody would selectively recognize the resulting aptamer–target complex. This approach might eventually enable the development of a sandwich-like detection system for small molecules that are difficult to measure using conventional antibody-based assays.
Looking ahead over the next five to ten years, the researchers noted that advances in aptamer design, antibody affinity maturation, and assay optimization could support the development of practical biosensors for food safety, environmental screening, and biotechnology. In particular, monitoring antibiotic residues in animal-derived food supplies represents a primary practical goal. However, the authors emphasized that further investigation remains necessary to design aptamers that undergo more pronounced structural shifts upon target binding and to validate reliable analytical performance across real-world testing environments.
Specially Appointed Professor Nemoto stated that the team’s long-term objective is to establish integrated molecular detection technologies by combining the distinct strengths of DNA aptamers and antibodies. If aptamers that change their structures more distinctly when capturing small molecules and antibodies that recognize those changes with high specificity can be designed, they may enable new detection tools for substances difficult to measure using existing methods, potentially contributing to safer food supplies, improved environmental monitoring, and broader molecular diagnostics.
Subject of Research: Recognition of DNA aptamer tertiary structure by single-domain VHH antibodies
Article Title: Saitama University research team finds an antibody that recognizes DNA shape and responds to antibiotic-induced structural changes
Article References: Saitama University research team finds an antibody that recognizes DNA shape and responds to antibiotic-induced structural changes. Original publication (Bibliographic details unavailable.)
Image Credits: AI Generated
DOI: Not provided
Keywords: VHH antibody, DNA aptamer, oxytetracycline, cDNA display, AlphaFold3, surface plasmon resonance, molecular recognition, tertiary structure, biosensors, structural biology, single-domain antibody, Saitama University, in vitro selection, antibiotic detection, biotechnology
News Source: Drew Townsend. (November 20, 2026). Engineered VHH Antibody Recognizes DNA Aptamer Shape and Antibiotic Binding. Scienmag.



